Everlife Capital

I research longevity biotechs and early-stage companies focusing on healthspan potential and financial metrics to solve the problem of aging (for informational purposes only; not investment or medical advice).

Latest

Something Is Happening In Your Body Right Now. You Cannot Feel It Yet.

Mar 18, 2026

Why age-related muscle decline may become one of the most important longevity investment themes of the next decade, and how I think about Dual ROI before the market catches up.

The 2026 Epigenetic Reprogramming Watchlist: 5 Companies Working To Reset Cellular Age

Mar 17, 2026

Big Pharma Has $236 Billion Disappearing by 2030. Let's Look At What They Might Be Looking For.

Mar 16, 2026

I Learned This From Selling Part Of My Company. Build What The Buyer Already Needs. Then Overlap It With What May Keep Us Alive.

Start With The End in Mind: How Big Pharma Actually Decides Which Biotech Companies to Acquire

Mar 11, 2026

I've watched dozens of companies in my 411-company longevity universe get acquired. A pattern kept repeating. Then I remembered selling part of CuraDebt - and realized biotech M&A works exactly the same way.

The Muscle Problem Nobody Is Talking About

Mar 9, 2026

Sarcopenia, The Science Of Saving Your Strength, And The Companies I Am Watching Right Now